Liver cancer drug combo gets its second FDA rejection
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug combination to treat the most common form of liver cancer. Korean biotech HLB and China-based Hengrui were applied to...
View ArticleTeenager dies after receiving Sarepta therapy; Immunovant gets Phase 3 win,...
Hello and welcome back to the new Endpoints Weekly. It was another busy week in the biopharma world and we’ve got all of the headlines for you below. We also had an
View ArticleBelgian biotech Augustine gets $85M for neuro and cardiometabolic pills
Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take on Charcot-Marie-Tooth disease, neurodegenerative conditions and cardiometabolic disorders. Two of Europe's leading...
View Article23andMe files for bankruptcy, CEO Wojcicki steps down
Rounding off a turbulent few years, genetic testing company 23andMe is filing for bankruptcy. CEO Anne Wojcicki has resigned after three failed attempts at taking the company private and in a ...
View ArticleTempero Bio, led by ex-Novartis execs, gets $70M to reduce substance use...
A small Oakland, CA-based biotech hoping to take on the sprawling landscape of substance use disorders and addiction has reeled in $70 million. The drug development startup, named Tempero Bio, secured...
View ArticleBiogen plans to open new headquarters in Boston area in 2028
Biogen announced on Monday its plans to launch a new headquarters outside Boston, aiming to consolidate its research and development teams alongside its commercial operations. The building is located...
View ArticleNovo Nordisk pays $200M upfront for United Laboratories International...
Novo Nordisk is not immune to the trend of seeking obesity assets from China-based biotechs, and the Danish drugmaker will pay United Laboratories International Holdings $200 million upfront for an...
View ArticleSurrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund
Plus, news about CG Oncology, Opus Genetics and Valneva: Surrozen’s pivot and capital raise: The South San Francisco drug developer is scrapping clinical development in severe alcohol associated...
View ArticleTwo biotechs fail to beat or match Regeneron's Eylea in key trials
Opthea and Unity Biotechnology, which are both developing new drugs for eye diseases, were unable to beat or match aflibercept, the standard-of-care treatment that Regeneron markets as Eylea, in two...
View ArticleFDA's biologics chief stresses need for vaccine transmission data
Incorporating disease transmission data into vaccine trial designs could add to their benefit-risk calculus, even though it will likely make vaccines more costly to develop, Peter Marks, chief of the...
View ArticleAbbVie files suit against Genmab subsidiary ProfoundBio
AbbVie has accused a Genmab subsidiary of stealing trade secrets to build a potential competitor to its ovarian cancer treatment Elahere. In a lawsuit filed on Friday in Washington federal court,...
View ArticleTrump pharma tariffs: Details on impact and timing
President Donald Trump reiterated his plans to “at some point" put tariffs on pharmaceutical goods made outside the US, taking another step toward a trade policy that the industry has been trying to...
View ArticleTrump taps acting CDC chief Susan Monarez for permanent role
President Donald Trump has nominated acting CDC director Susan Monarez to lead the agency. He posted his decision Monday on Truth Social, saying that Monarez “understands the importance of protecting...
View ArticleMerck and Hengrui strike $2B deal for Lipoprotein(a) drug
Merck has struck a licensing deal for a cardiovascular drug with Jiangsu Hengrui Pharmaceuticals, the latest in a flood of China deals being made by US and European multinationals. Under the deal,...
View ArticleHillstar Bio raises $67M for immunology drugs
The flurry of immunology biotech launches continues. Boston-based Hillstar Bio on Tuesday became the latest immunology startup launch, unveiling a $67 million Series A round funded by Droia Ventures,...
View ArticleGSK to research whether shingles vaccine can cut dementia risk
GSK is teaming up with a pair of UK-based research bodies to conduct a “real world evidence analysis” to see if its shingles vaccine Shingrix can cut the risk of developing dementia. Together with the ...
View ArticleOphthalmology startup Character Biosciences gets $93M for genetics-based...
Seven years into its existence, Character Biosciences is ready to enter the clinic with a pair of experimental medicines targeting a bustling area of ophthalmology. The New Jersey biotech aims to treat...
View ArticleCassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken
Plus, news about Relmada Therapeutics and Mural Oncology: Cassava Sciences finally stops work on Alzheimer’s drug: After a Phase 3 study of simufilam failed in November, Cassava said it was...
View ArticleKezar toplines small Phase 2a dataset in autoimmune liver disease
Kezar reported new data Tuesday morning from a small Phase 2a study in autoimmune hepatitis, or AIH, a condition where the immune system attacks the liver. The company tested its drug zetomipzomib in a...
View ArticleWuXi Biologics’ licensing deals help offset Biosecure threat in the US
WuXi Biologics attributed a 32.5% increase in North American revenue last year to out-licensing deals with global drugmakers despite the "dynamic political environment” in the US. That’s compared to...
View Article